Andrew Tsai
Stock Analyst at Jefferies
(4.78)
# 543
Out of 4,371 analysts
153
Total ratings
56.8%
Success rate
24.8%
Average return
Main Sectors:
Stocks Rated by Andrew Tsai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DFTX Definium Therapeutics | Maintained: Buy | $30 → $35 | $24.59 | +42.33% | 3 | May 21, 2026 | |
| CMPS COMPASS Pathways | Maintained: Buy | $18 | $13.05 | +37.93% | 2 | May 14, 2026 | |
| ANRO Alto Neuroscience | Maintained: Buy | $35 | $20.03 | +74.74% | 8 | May 14, 2026 | |
| MRNA Moderna | Maintained: Hold | $30 → $45 | $51.59 | -12.77% | 6 | May 12, 2026 | |
| AXSM Axsome Therapeutics | Maintained: Buy | $200 | $231.48 | -13.60% | 2 | May 1, 2026 | |
| CSE: DRUG Bright Minds Biosciences Inc. | Initiated Coverage: Buy | $201.53 | $102.67 | +96.29% | 1 | Apr 12, 2026 | |
| BBIO BridgeBio Pharma | Maintained: Buy | $100 | $67.33 | +48.52% | 9 | Mar 31, 2026 | |
| PRAX Praxis Precision Medicines | Maintained: Buy | $450 → $525 | $264.75 | +98.30% | 6 | Mar 31, 2026 | |
| BIIB Biogen | Maintained: Buy | $210 | $196.45 | +6.90% | 6 | Mar 12, 2026 | |
| XENE Xenon Pharmaceuticals | Rated: Buy | $65 → $100 | $52.99 | +88.71% | 24 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $4.50 | +122.22% | 11 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $22 | $4.43 | +396.61% | 1 | Feb 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $35 → $30 | $16.66 | +80.07% | 12 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $7.5 | $6.25 | +20.00% | 1 | Dec 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $15 → $0.9 | $0.5756 | +56.36% | 5 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $3 → $5 | $4.78 | +4.60% | 2 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $30 | $30.12 | -0.40% | 2 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $32 | $30.10 | +6.31% | 1 | Nov 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $5.45 | +83.49% | 7 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $2.5 → $3 | $2.92 | +2.74% | 5 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $3 → $0.85 | $1.90 | -55.26% | 2 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8.5 | $5.30 | n/a | 7 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $40 | $44.70 | n/a | 9 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $35 | $37.49 | n/a | 3 | Dec 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $3 → $0.5 | $8.61 | n/a | 9 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $75 → $13 | $6.31 | n/a | 4 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $42 | $18.41 | n/a | 5 | Jun 24, 2024 |
Definium Therapeutics
May 21, 2026
Maintained: Buy
Price Target: $30 → $35
Current: $24.59
Upside: +42.33%
COMPASS Pathways
May 14, 2026
Maintained: Buy
Price Target: $18
Current: $13.05
Upside: +37.93%
Alto Neuroscience
May 14, 2026
Maintained: Buy
Price Target: $35
Current: $20.03
Upside: +74.74%
Moderna
May 12, 2026
Maintained: Hold
Price Target: $30 → $45
Current: $51.59
Upside: -12.77%
Axsome Therapeutics
May 1, 2026
Maintained: Buy
Price Target: $200
Current: $231.48
Upside: -13.60%
Bright Minds Biosciences Inc.
Apr 12, 2026
Initiated Coverage: Buy
Price Target: $201.53
Current: $102.67
Upside: +96.29%
BridgeBio Pharma
Mar 31, 2026
Maintained: Buy
Price Target: $100
Current: $67.33
Upside: +48.52%
Praxis Precision Medicines
Mar 31, 2026
Maintained: Buy
Price Target: $450 → $525
Current: $264.75
Upside: +98.30%
Biogen
Mar 12, 2026
Maintained: Buy
Price Target: $210
Current: $196.45
Upside: +6.90%
Xenon Pharmaceuticals
Mar 9, 2026
Rated: Buy
Price Target: $65 → $100
Current: $52.99
Upside: +88.71%
Mar 9, 2026
Maintained: Buy
Price Target: $10
Current: $4.50
Upside: +122.22%
Feb 1, 2026
Initiated Coverage: Buy
Price Target: $22
Current: $4.43
Upside: +396.61%
Jan 12, 2026
Maintained: Buy
Price Target: $35 → $30
Current: $16.66
Upside: +80.07%
Dec 31, 2025
Maintained: Hold
Price Target: $7.5
Current: $6.25
Upside: +20.00%
Dec 17, 2025
Downgraded: Hold
Price Target: $15 → $0.9
Current: $0.5756
Upside: +56.36%
Dec 1, 2025
Maintained: Hold
Price Target: $3 → $5
Current: $4.78
Upside: +4.60%
Nov 24, 2025
Maintained: Buy
Price Target: $30
Current: $30.12
Upside: -0.40%
Nov 21, 2025
Initiated Coverage: Buy
Price Target: $32
Current: $30.10
Upside: +6.31%
Nov 11, 2025
Maintained: Buy
Price Target: $10
Current: $5.45
Upside: +83.49%
Aug 8, 2025
Maintained: Hold
Price Target: $2.5 → $3
Current: $2.92
Upside: +2.74%
Aug 6, 2025
Maintained: Hold
Price Target: $3 → $0.85
Current: $1.90
Upside: -55.26%
Mar 26, 2025
Maintained: Buy
Price Target: $8.5
Current: $5.30
Upside: n/a
Mar 12, 2025
Reiterated: Buy
Price Target: $40
Current: $44.70
Upside: n/a
Dec 7, 2024
Rated: Buy
Price Target: $35
Current: $37.49
Upside: n/a
Sep 18, 2024
Rated: Hold
Price Target: $3 → $0.5
Current: $8.61
Upside: n/a
Sep 16, 2024
Upgraded: Buy
Price Target: $75 → $13
Current: $6.31
Upside: n/a
Jun 24, 2024
Maintained: Buy
Price Target: $42
Current: $18.41
Upside: n/a